Published: April 2026

CPS is honored to announce the publication of our 2026 Patient Impact Report. This is the fifth annual edition of our comprehensive resource with the latest HSSP outcomes measurement and benchmark data and best practices from organizations across the nation to compare against your own.

Specialty pharmacy not only generates new revenue for health systems to reinvest, but it also elevates patient care through outcomes measurement and improvement as detailed in this new report.

— Latest clinical benchmarks and outcomes measurement strategies for chronic conditions

           •  Asthma & COPD

           •  Autoimmune Disorders

                    → Dermatology: Atopic Dermatitis (AD) & Plaque Psoriasis (PsO)

                    → Gastroenterology: Inflammatory Bowel Disease (IBD) - Crohn's Disease (CD) &                                                 Ulcerative Colitis (UC)

                    → Rheumatology: Rheumatoid Arthritis (RA), Psoriatic Arthritis (PsA), & Ankylosing                                            Spondylitis (AS) 

         •  Cancer

         •  Diabetes & Obesity

         •  Hepatitis C Virus (HCV)

         •  Human Immunodeficiency Virus (HIV)

         •  Migraine

         •  Multiple Sclerosis (MS)

— Research findings on new and innovative patient care protocols from award-winning CPS outcomes studies and journal articles

 — Holistic patient care considerations to address social determinants of health (SDOH) and health-related social needs (HRSNs)

 — New trends on unique patient populations, including pediatrics and rare diseases, and how specialty pharmacy helps facilitate those patient journeys

 — Real-world testimonials from patients and providers about their experiences with their health system's specialty pharmacy

Fill out the form below to request a digital copy of the report.